Citations

Showing 10 of 108081 citations.

Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions
Kar, Siddhartha , Gayther, Simon A. , Goode, Ellen L. , Moysich, Kirsten B., Pearce, Celeste Leigh, Ramus, Susan J. , Schildkraut, Joellen M. , Sellers, Thomas A. , Berchuck, Andrew , Pharoah, Paul D.P. , Ramus, Susan J , Moysich, Kirsten , Kar, Siddhartha

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 14, 2017 | Volume: 27 | Issue: 4 | Pages: 395-404

10.1158/1055-9965.epi-17-0315 | PMID 28615364 Get It

Abstract In this review, we summarize current progress in the genetic epidemiology of epithelial ovarian cancer (EOC), focusing exclusively on elucidating the role of common germline genetic variation in conferring susceptibility to EOC. We provide an overview of the more than 30 EOC risk loci identified to date by genome-wide association studies (GWAS) and describe the contribution of large-scale, cross-cancer type, custom genotyping projects, such as the OncoArray and the Collaborative Oncological Gene-Environment Study, to locus discovery and replication. We discuss the histotype-specific nature of these EOC risk loci, pleiotropy, or overlapping genetic effects between EOC and other hormone-related cancer types, and the application of findings to polygenic risk prediction for EOC. The second part of the article offers a concise review of primarily laboratory-based studies that have led to the identification of several putative EOC susceptibility genes using common variants at the known EOC risk loci as starting points. More global biological insights emerging from network- and pathway-based analyses of GWAS for EOC susceptibility are also highlighted. Finally, we delve into potential future directions, including the need to identify EOC risk loci in non-European populations and the next generation of GWAS functional studies that are likely to involve genome editing to establish the cell type–specific carcinogenic effects of EOC risk variants Cancer Epidemiol Biomarkers Prev; 27(4); 395–404. ©2018 AACR. See all articles in this CEBP Focus section, “Genome-Wide Association Studies in Cancer.”
The regulatory 1α subunit of protein kinase A modulates renal cystogenesis
Ye, Hong , Constans, Megan, Sussman, Caroline R. , Irazabal, María V. , Harris, Peter C. , Kirschner, Lawrence S. , Torres, Vicente E. , Constans, Megan M, Ye, Hong, Wang, Xiaofang , Chebib, Fouad T. , Young, William F. , Harris, Peter C , Torres, Vicente E , Irazabal, Maria V , Sussman, Caroline R.

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 14, 2017 | Volume: 313 | Issue: 3 | Pages: F677-F686

10.1152/ajprenal.00119.2017 | PMID 28615245 Get It

The failure of the polycystins (PCs) to function in primary cilia is thought to be responsible for autosomal dominant polycystic kidney disease (ADPKD). Primary cilia integrate multiple cellular signaling pathways, including calcium, cAMP, Wnt, and Hedgehog, which control cell proliferation and differentiation. It has been proposed that mutated PCs result in reduced intracellular calcium, which in turn upregulates cAMP, protein kinase A (PKA) signaling, and subsequently other proliferative signaling pathways. However, the role of PKA in ADPKD has not been directly ascertained in vivo, although the expression of the main regulatory subunit of PKA in cilia and other compartments (PKA-RIα, encoded by PRKAR1A) is increased in a mouse model orthologous to ADPKD. Therefore, we generated a kidney-specific knockout of Prkar1a to examine the consequences of constitutive upregulation of PKA on wild-type and Pkd1 hypomorphic ( Pkd1 RC ) backgrounds. Kidney-specific loss of Prkar1a induced renal cystic disease and markedly aggravated cystogenesis in the Pkd1 RC models. In both settings, it was accompanied by upregulation of Src, Ras, MAPK/ERK, mTOR, CREB, STAT3, Pax2 and Wnt signaling. On the other hand, Gli3 repressor activity was enhanced, possibly contributing to hydronephrosis and impaired glomerulogenesis in some animals. To assess the relevance of these observations in humans we looked for and found evidence for kidney and liver cystic phenotypes in the Carney complex, a tumoral syndrome caused by mutations in PRKAR1A. These observations expand our understanding of the pathogenesis of ADPKD and demonstrate the importance of PRKAR1A highlighting PKA as a therapeutic target in ADPKD.
Assessment and Treatment of Syncope
Shen, Win-Kuang, Sheldon, Robert S.

Mayo Clinic

JAMA Cardiology | June 14, 2017 | Volume: 2 | Issue: 8 | Pages: 920

10.1001/jamacardio.2017.1784 | PMID 28614562 Get It

The Almost-Normal Liver Biopsy
Czeczok, Thomas , Arnam, John S. Van , Wood, Laura D. , Mounajjed, Taofic, Czeczok, Thomas W, Torbenson, Michael

Mayo Clinic

American Journal of Surgical Pathology | June 14, 2017 | Volume: 41 | Issue: 9 | Pages: 1247-1253

10.1097/pas.0000000000000881 | PMID 28614198 Get It

Liver biopsies obtained for abnormal liver enzymes or unexplained ascites occasionally appear histologically almost normal. The differential diagnosis for these cases is challenging because literature addressing this topic is lacking. We aimed to establish a differential diagnosis and determine clinical associations and outcomes for almost-normal liver biopsies. Ninety-seven histologically almost-normal liver biopsies were collected from 2 institutions. All cases lacked significant inflammation, fatty change, biliary tract disease, vascular disease, nodular regenerative hyperplasia, iron overload, inherited metabolic or storage disorder, viral hepatitis, or fibrosis. Biopsies for follow-up of known liver diseases were excluded. Transplant biopsies, lesion-directed biopsies, biopsies obtained during bariatric surgery, liver donor biopsies, and biopsies to evaluate methotrexate toxicity were excluded. Clinical (including follow-up) and laboratory data were collected. The frequency of almost-normal liver biopsies was 0.6% and 3.7% at the 2 institutions. The most common biopsy indications were elevated liver biochemistries or clinical findings that suggested portal hypertension. In 70 patients (72%), an associated clinical abnormality was identified; the most common were autoimmune systemic inflammatory conditions (18%), vascular/ischemic events (13%), metabolic syndrome (11%), drug effects (8%), and inflammatory conditions of the gastrointestinal tract (7%). The median follow-up period was 4.3 years (range=0 to 10 y); detailed clinical follow-up was available for 66 patients (68%). Liver biochemistries normalized in 32 patients (48.5%) and remained elevated in 34 (51.5%). Seven patients (7.2%) eventually developed chronic liver disease (autoimmune hepatitis [n=3], primary biliary cirrhosis [n=3], cryptogenic cirrhosis [n=1]). This multicenter study determines the differential diagnosis for almost-normal liver biopsies; this will guide pathologists in subsequent workup efforts in these challenging cases.
Analysis of a Physician-led, Team-based Care Model for the Treatment of Glaucoma
Winkler, Nelson S., Damento, Gena M., Khanna, Sunil S., Hodge, David O. , Khanna, Cheryl L.

Mayo Clinic

Journal of Glaucoma | June 14, 2017 | Volume: 26 | Issue: 8 | Pages: 702-707

10.1097/ijg.0000000000000689 | PMID 28617721 Get It

Purpose: To determine the effect of a protocol for a new physician-led, team-based glaucoma care model implemented in 2008 at Mayo Clinic’s campus in Rochester, Minnesota (MCR), to increase conformance with the American Academy of Ophthalmology (AAO) Preferred Practice Pattern guidelines for treatment of primary open-angle glaucoma. Methods: Records of 591 patients with newly diagnosed glaucoma were assessed retrospectively for the completion of 9 AAO Preferred Practice Pattern recommended metrics including measured corneal thickness, intraocular pressure (IOP), cup to disk ratio, visual acuity, recorded IOP target, gonioscopy, fundus photos, ocular coherence tomography, and visual field in the 3 years before and 3 years after protocol implementation. Treatment by the glaucoma care team at MCR was compared with treatment at a community-based general ophthalmology practice and with a group of comprehensive ophthalmologists at MCR without team care, which served as controls. Results: Adherence to AAO recommendations increased for the documentation of target IOP (+24%, 42.6% to 66.7%; P=0.007), gonioscopy (+27%, 66.7% to 93.3%; P≤0.001), fundus photos (+29%, 44.4% to 73.3%; P≤0.001), and ocular coherence tomography (+20%, 48.1% to 68.0%; P=0.02) after protocol initiation. No change in pattern of testing occurred in the control groups without team care during the same time period. Type and severity of glaucoma were similar between MCR and community practice. Conclusions: An increase in compliance with AAO guidelines was found after implementation of our protocol for a physician-led, team-based care model to standardize glaucoma care among providers.
Importance of Artificial Pancreas Standard Nomenclature
Basu, Ananda

Mayo Clinic

Diabetes Technology & Therapeutics | June 14, 2017 | Volume: 19 | Issue: 6 | Pages: 323-323

10.1089/dia.2017.0169 | PMID 28613949 Get It

Early‐life decline in neurogenesis markers and age‐related changes of TrkB splice variant expression in the human subependymal zone
Weissleder, Christin , Kondo, Mari , Yang, Chunhui , Fung, Samantha J., Rothmond, Debora A. , Wong, Matthew Wai Kin , Halliday, Glenda M. , Herman, Mary M., Weickert, Cynthia Shannon , Kleinman, Joel E , Webster, Maree J. , Halliday, Glenda , Weissleder, Christin

Mayo Clinic

European Journal of Neuroscience | June 14, 2017 | Volume: 46 | Issue: 2 | Pages: 1768-1778

10.1111/ejn.13623 | PMID 28612959 Get It

AbstractNeurogenesis in the subependymal zone (SEZ) declines across the human lifespan, and reduced local neurotrophic support is speculated to be a contributing factor. While tyrosine receptor kinase B (TrkB) signalling is critical for neuronal differentiation, maturation and survival, little is known about subependymal TrkB expression changes during postnatal human life. In this study, we used quantitative PCR and in situ hybridisation to determine expression of the cell proliferation marker Ki67, the immature neuron marker doublecortin (DCX) and both full‐length (TrkB‐TK+) and truncated TrkB receptors (TrkB‐TK‐) in the human SEZ from infancy to middle age (n = 26–35, 41 days to 43 years). We further measured TrkB‐TK+ and TrkB‐TK‐ mRNAs in the SEZ from young adulthood into ageing (n = 50, 21–103 years), and related their transcript levels to neurogenic and glial cell markers. Ki67, DCX and both TrkB splice variant mRNAs significantly decreased in the SEZ from infancy to middle age. In contrast, TrkB‐TK‐ mRNA increased in the SEZ from young adulthood into ageing, whereas TrkB‐TK+ mRNA remained stable. TrkB‐TK‐ mRNA positively correlated with expression of neural precursor (glial fibrillary acidic protein delta and achaete‐scute homolog 1) and glial cell markers (vimentin and pan glial fibrillary acidic protein). TrkB‐TK+ mRNA positively correlated with expression of neuronal cell markers (DCX and tubulin beta 3 class III). Our results indicate that cells residing in the human SEZ maintain their responsiveness to neurotrophins; however, this capability may change across postnatal life. We suggest that TrkB splice variants may differentially influence neuronal and glial differentiation in the human SEZ.
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Casuscelli, Jozefina , Gundem, Gunes , Wang, Lu , Zabor, Emily C. , Drill, Esther , Wang, Patricia I., Nanjangud, Gouri J. , Redzematovic, Almedina, Nargund, Amrita M. , Manley, Brandon J. , Arcila, Maria E. , Donin, Nicholas M. , Cheville, John C. , Thompson, R. Houston, Pantuck, Allan J., Russo, Paul , Cheng, Emily H. , Lee, William , Tickoo, Satish K. , Ostrovnaya, Irina , Creighton, Chad J. , Papaemmanuil, Elli , Seshan, Venkatraman , Hsieh, James J. , Weinhold, Nils , Hakimi, A Ari , Manley, Brandon J

Mayo Clinic

JCI Insight | June 14, 2017 | Volume: 2 | Issue: 12 | Pages: No page available

10.1172/jci.insight.92688 | PMID 28614790 Get It

Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%–10% metastatic incidence. Since extensive chromosomal losses can generate proteotoxic stress and compromise cellular proliferation, it is intriguing how chRCC, a tumor with extensive chromosome losses and a low number of somatic mutations, can develop lethal metastases. Genomic features distinguishing metastatic from nonmetastatic chRCC are unknown. An integrated approach, including whole-genome sequencing (WGS), targeted ultradeep cancer gene sequencing, and chromosome analyses (FACETS, OncoScan, and FISH), was performed on 79 chRCC patients including 38 metastatic (M-chRCC) cases. We demonstrate that TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC. Reconstruction of the subclonal composition of paired primary-metastatic chRCC tumors supports the role of TP53 , PTEN , and ICD in metastatic evolution. Finally, the presence of these 3 genomic features in primary tumors of both The Cancer Genome Atlas kidney chromophobe (KICH) ( n = 64) and M-chRCC ( n = 35) cohorts was associated with worse survival. In summary, our study provides genomic insights into the metastatic progression of chRCC and identifies TP53 mutations, PTEN mutations, and ICD as high-risk features.
Midostaurin for the treatment of acute myeloid leukemia
Patnaik, Mrinal M.

Mayo Clinic

Future Oncology | June 14, 2017 | Volume: 13 | Issue: 21 | Pages: 1853-1871

10.2217/fon-2017-0160 | PMID 28610444 Get It